Eli Lilly (LLY)
(Delayed Data from NYSE)
$891.07 USD
+6.59 (0.75%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $891.10 +0.03 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$891.07 USD
+6.59 (0.75%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $891.10 +0.03 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value F Growth B Momentum F VGM
Zacks News
Array BioPharma Gains on Colorectal Cancer Study Success
by Zacks Equity Research
Array BioPharma's (ARRY) phase III study, evaluating the Braftovi triplet for treating metastatic colorectal cancer, meets the primary goal of ORR and OS. Shares rally.
3 Tech Stocks for Growth Investors to Buy Right Now
by Benjamin Rains
Now it's time to check out three tech stocks that came through our screen today that growth investors might want to consider buying right now.
Lilly's Crohn's Disease Candidate Meets Phase II Study Goals
by Zacks Equity Research
Lilly's (LLY) mirikizumab met primary endpoint and key secondary endpoints in phase II Crohn's disease study.
Merck to Buy Private Cancer Drugmaker Peloton Therapeutics
by Zacks Equity Research
Merck (MRK) signs a definitive agreement to buy small private biotech, Peloton Therapeutics for $1.05 billion in cash to boost its oncology pipeline.
Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs
by Kinjel Shah
FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs
Pfizer's Eczema Candidate Meets All Goals in Phase III Study
by Zacks Equity Research
Pfizer's (PFE) investigational eczema treatment abrocitinib succeeds in pivotal late-stage study.
The Zacks Analyst Blog Highlights: Alphabet, Eli Lilly, CVS, Marriott and TELUS
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alphabet, Eli Lilly, CVS, Marriott and TELUS
Lilly's Cyramza Gets FDA Nod for Second-Line Liver Cancer
by Zacks Equity Research
Lilly's (LLY) Cyramza gets FDA approval to treat AFP-high hepatocellular carcinoma (HCC), a common form of liver cancer. FDA removes boxed warning from label.
Top Research Reports for Alphabet, Eli Lilly & CVS Health
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Eli Lilly (LLY) and CVS Health (CVS).
Radius (RDUS) Posts Narrower Q1 Loss, Misses on Revenues
by Zacks Equity Research
Radius Health (RDUS) posts narrower-than-expected Q1 loss but Tymlos sales disappoint.
Allergan (AGN) Beats on Q1 Earnings & Sales, Raises '19 View
by Zacks Equity Research
Allergan's (AGN) stock declines slightly in pre-market trading despite the company delivering earnings and revenue beat in the first quarter while marginally raising its guidance
Novo Nordisk (NVO) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Novo Nordisk's (NVO) earnings and sales miss estimates in the first quarter of 2019.
Teva (TEVA) Q1 Earnings Beat, Copaxone Drags Sales Down
by Zacks Equity Research
Teva Pharmaceutical (TEVA) beats estimates for earnings but misses the same for sales. Blockbuster drug Copaxone sales continue to erode amid generic competition.
Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV Drugs Get EU Nod
by Kinjel Shah
Merck (MRK), Pfizer (PFE), Lilly (LLY) announce Q1 results. European Commission grants approval to AbbVie's (ABBV) Skyrizi and Sanofi's (SNY) Zynquista.
United Therapeutics (UTHR) Down Despite Q1 Earnings Beat
by Zacks Equity Research
United Therapeutics (UTHR) beats estimates on both fronts in the first quarter. However, earnings and revenues decline year over year.
Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Amgen (AMGN) Q1 Earnings Top, Sales Hurt by Pricing Pressure
by Zacks Equity Research
Amgen (AMGN) earnings beat estimates in the first quarter while sales come in line with the same. The company raises the lower end of its previously issued sales and earnings guidance for 2019.
3 Tech Stocks for Growth Investors to Buy Right Now
by Benjamin Rains
Let's check out three tech stocks that came through our screen today that growth investors might want to consider at the moment...
Lilly (LLY) Down Despite Q1 Earnings Beat on Sales View Cut
by Zacks Equity Research
Eli Lilly's (LLY) earnings beat estimates in Q1. Stock falls in pre-market trading as the company lowers its full-year revenue forecast.
Incyte (INCY) Q1 Earnings & Revenues Beat Estimates, Up Y/Y
by Zacks Equity Research
While Incyte's (INCY) earnings and revenues beat estimates in Q1, Jakafi sales fall short of the same.
Looking for a Growth Stock? 3 Reasons Why Lilly (LLY) is a Solid Choice
by Zacks Equity Research
Lilly (LLY) is well positioned to outperform the market, as it exhibits above-average growth in financials.
5 Drug/Biotech Stocks Poised to Beat Q1 Earnings Estimates
by Zacks Equity Research
So far, the going seems good for the drug/biotech sector this earnings season. Let us take a glance at a few other companies, which hold promise to beat on Q1 earnings.
AstraZeneca's (AZN) Q1 Earnings Beat, New Drugs Drive Sales
by Zacks Equity Research
AstraZeneca (AZN) beats earnings and sales estimates in the first quarter. New drugs, especially cancer drugs, drive revenues.
Sanofi (SNY) Q1 Earnings Top, Genzyme & Vaccines Drive Sales
by Zacks Equity Research
Sanofi's first-quarter 2019 results were mixed as it beat estimates for earnings but missed the same for sales.